• Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 159.12 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.42
▲ +0.04 (0.39%)

This chart shows the closing price for IMTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immatics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMTX

Analyst Price Target is $27.00
▲ +159.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Immatics in the last 3 months. The average price target is $27.00, with a high forecast of $28.00 and a low forecast of $26.00. The average price target represents a 159.12% upside from the last price of $10.42.

This chart shows the closing price for IMTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Immatics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2022Chardan CapitalLower TargetBuy$30.00 ➝ $28.00Low
6/3/2022SVB LeerinkBoost TargetOutperform$25.00 ➝ $26.00Medium
3/24/2022SVB LeerinkLower TargetOutperform$32.00 ➝ $25.00Medium
12/14/2021SVB LeerinkBoost TargetOutperform ➝ Outperform$28.00 ➝ $32.00High
7/15/2021SVB LeerinkBoost TargetOutperform$26.00 ➝ $27.00Medium
7/7/2021Chardan CapitalReiterated RatingBuyLow
5/23/2021SVB LeerinkReiterated RatingBuy$26.00Low
4/4/2021Chardan CapitalReiterated RatingBuyMedium
3/17/2021SVB LeerinkBoost TargetOutperform$17.00 ➝ $26.00High
11/20/2020Bank of AmericaInitiated CoverageBuy$13.00Low
9/21/2020The Goldman Sachs GroupInitiated CoverageBuy$17.00High
8/18/2020Chardan CapitalReiterated RatingBuy$28.00Medium
7/27/2020SVB LeerinkInitiated CoverageOutperform$17.00High
7/24/2020Jefferies Financial GroupInitiated CoverageBuy$14.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/6/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/6/2022

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Positive

Immatics logo
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Read More

Today's Range

Now: $10.42
Low: $10.22
High: $10.51

50 Day Range

MA: $11.29
Low: $8.97
High: $13.06

52 Week Range

Now: $10.42
Low: $5.75
High: $14.90

Volume

54,331 shs

Average Volume

237,156 shs

Market Capitalization

$655.52 million

P/E Ratio

21.71

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Immatics?

The following sell-side analysts have issued stock ratings on Immatics in the last twelve months: Chardan Capital, and SVB Leerink LLC.
View the latest analyst ratings for IMTX.

What is the current price target for Immatics?

2 Wall Street analysts have set twelve-month price targets for Immatics in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 159.1%. Chardan Capital has the highest price target set, predicting IMTX will reach $28.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $26.00 for Immatics in the next year.
View the latest price targets for IMTX.

What is the current consensus analyst rating for Immatics?

Immatics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMTX will outperform the market and that investors should add to their positions of Immatics.
View the latest ratings for IMTX.

What other companies compete with Immatics?

How do I contact Immatics' investor relations team?

Immatics' physical mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The company's listed phone number is 49-7071-539-7700. The official website for Immatics is www.immatics.com. Learn More about contacing Immatics investor relations.